| Primary |
| Toxoplasmosis |
31.8% |
| Eye Infection Toxoplasmal |
15.9% |
| Choroiditis |
13.6% |
| Cerebral Toxoplasmosis |
9.1% |
| Prophylaxis |
6.8% |
| Pemphigus |
4.5% |
| Pyoderma Gangrenosum |
4.5% |
| Blister |
2.3% |
| Central Nervous System Infection |
2.3% |
| Pneumocystis Jiroveci Infection |
2.3% |
| Premature Labour |
2.3% |
| Rheumatoid Arthritis |
2.3% |
| Skin Ulcer |
2.3% |
|
| Renal Failure |
17.2% |
| Renal Failure Acute |
10.3% |
| Vomiting |
10.3% |
| Rash |
6.9% |
| Abdominal Pain |
3.4% |
| Argyria |
3.4% |
| Burning Sensation |
3.4% |
| Candida Infection |
3.4% |
| Drug Hypersensitivity |
3.4% |
| Haematuria |
3.4% |
| Liver Injury |
3.4% |
| Medication Error |
3.4% |
| Nephropathy Toxic |
3.4% |
| Parosmia |
3.4% |
| Pneumonitis |
3.4% |
| Polyuria |
3.4% |
| Rash Pruritic |
3.4% |
| Renal Haemorrhage |
3.4% |
| Septic Shock |
3.4% |
| Staphylococcal Infection |
3.4% |
|
| Secondary |
| Product Used For Unknown Indication |
28.1% |
| Drug Abuse |
18.1% |
| Drug Use For Unknown Indication |
11.7% |
| Hiv Infection |
7.4% |
| Cerebral Toxoplasmosis |
7.1% |
| Toxoplasmosis |
4.8% |
| Acquired Immunodeficiency Syndrome |
2.5% |
| Supplementation Therapy |
2.4% |
| Agitation |
2.1% |
| Epilepsy |
2.0% |
| Eye Infection Toxoplasmal |
2.0% |
| Opportunistic Infection Prophylaxis |
1.9% |
| Sepsis |
1.8% |
| Hypertension |
1.6% |
| Ear Infection |
1.3% |
| Hallucination |
1.1% |
| Mycobacterium Avium Complex Infection |
1.1% |
| Thrombosis Prophylaxis |
1.1% |
| Paracoccidioides Infection |
1.0% |
| Acne |
1.0% |
|
| Toxic Epidermal Necrolysis |
12.2% |
| Ventricular Extrasystoles |
8.9% |
| Thrombocytopenia |
7.8% |
| Hepatitis Cholestatic |
6.7% |
| Renal Failure Acute |
6.7% |
| Treatment Noncompliance |
6.7% |
| Stevens-johnson Syndrome |
5.6% |
| Drug Hypersensitivity |
4.4% |
| Neutropenia |
4.4% |
| Platelet Count Decreased |
4.4% |
| Rash |
4.4% |
| Vomiting |
4.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.3% |
| Hyperhidrosis |
3.3% |
| Loss Of Consciousness |
3.3% |
| Pyrexia |
3.3% |
| Toxic Skin Eruption |
3.3% |
| Agranulocytosis |
2.2% |
| Blood Creatinine Increased |
2.2% |
| Cytolytic Hepatitis |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.4% |
| Drug Use For Unknown Indication |
12.0% |
| Hiv Infection |
10.7% |
| Rheumatoid Arthritis |
8.6% |
| Fabry's Disease |
8.2% |
| Cerebral Toxoplasmosis |
4.3% |
| Pain |
3.6% |
| Toxoplasmosis |
3.4% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| Diabetes Mellitus |
2.6% |
| Prophylaxis |
2.5% |
| Hypertension |
2.3% |
| Crohn's Disease |
2.0% |
| Acute Myeloid Leukaemia |
1.4% |
| Cellulitis |
1.4% |
| Pyrexia |
1.4% |
| Adverse Event |
1.4% |
| Acquired Immunodeficiency Syndrome |
1.3% |
| Multiple Myeloma |
1.3% |
| Arthralgia |
1.2% |
|
| White Blood Cell Count Decreased |
9.9% |
| Vomiting |
8.8% |
| Skin Ulcer |
6.6% |
| Stevens-johnson Syndrome |
6.6% |
| Diarrhoea |
5.5% |
| Drug Ineffective |
5.5% |
| Mental Status Changes |
5.5% |
| Pyrexia |
5.5% |
| Renal Failure |
5.5% |
| Rheumatoid Arthritis |
5.5% |
| Neutropenia |
4.4% |
| Pneumonia |
4.4% |
| Anaemia |
3.3% |
| Colitis |
3.3% |
| Deafness |
3.3% |
| Deafness Unilateral |
3.3% |
| Death |
3.3% |
| Kaposi's Sarcoma |
3.3% |
| Lymphoma |
3.3% |
| Myocardial Infarction |
3.3% |
|
| Interacting |
| Hiv Infection |
23.1% |
| Product Used For Unknown Indication |
23.1% |
| Affective Disorder |
15.4% |
| Cerebral Toxoplasmosis |
15.4% |
| Bone Marrow Failure |
7.7% |
| Mood Disorder Due To A General Medical Condition |
7.7% |
| Prophylaxis |
7.7% |
|
|
